84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
CA 2398064 C · Owner: Levin, Elana · Inventors: Afar, Daniel E. H.; Challita-Eid, Pia M.; Levin, Elana
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A novel gene (designated 84P2A9) and its encoded protein is described. While 84P2A9 exhibits prostate and testis specific expression in normal adult tissue, it is aberrantly expressed multiple cancers including prostate testis, kidney, brain, bone, skin, ovarian breast, pancreas, colon, lymphocytic and lung cancers. Consequently 84P2A9 provides a diagnostic , and/or therapeutic target for cancers and the 84P2A9 gene or fragment , thereof or its encoded protein or a fragment thereof used to elicit an immune response.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 26, 2001 and granted December 18, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 26, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 26, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.